Allogene Therapeutics (ALLO) vs DiaMedica Therapeutics (DMAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
DiaMedica Therapeutics (DMAC) has outperformed Allogene Therapeutics (ALLO) over the past year, gaining 15.0% versus a gain of 6.5%. Over five years, DMAC leads with a +88.3% price change compared with -91.7% for ALLO. Allogene Therapeutics is the larger company by market cap ($452.6 million vs $408.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | DMAC |
|---|---|---|
| Share price | $1.31 | $7.57 |
| Market cap | $452.59M | $408.22M |
| 1-day change | -2.24% | -5.85% |
| YTD return | -4.38% | -4.90% |
| 1-year return | +6.50% | +15.05% |
| 5-year return | -91.72% | +88.31% |
| EPS (TTM) | $-0.66 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-190.89M | $-32.77M |
| 52-week high | $4.46 | $10.42 |
| 52-week low | $1.04 | $5.25 |
| Distance from 52-week high | -70.63% | -27.35% |
| Analyst consensus | none | none |
| Avg. price target upside | +587.02% | +104.76% |
| Average volume | 5.66M | 182.81K |
| Shares outstanding | 345.49M | 53.93M |
| Employees | 150 | 35 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Healthcare · Biotechnology · 150 employees
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Healthcare · Biotechnology · 35 employees
ALLO vs DMAC FAQ
Which is bigger, Allogene Therapeutics or DiaMedica Therapeutics?
Allogene Therapeutics (ALLO) is larger, with a market capitalization of $452.59M compared with $408.22M for DiaMedica Therapeutics (DMAC).
Which stock has performed better over the past year, ALLO or DMAC?
DMAC returned +15.05% over the past 12 months, compared with +6.50% for ALLO (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and DiaMedica Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.